APOGEE THERAPEUTICS INC

APGENASDAQ

🏆 #688 by market capEarnings Nov 9US Equity

$134.69▲ $0.04 (+0.03%)

Live

1h—

24h▲ 0.0%

7d—

14d—

30d—

1y—

🏦Market Cap

$10.15B

Mid Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

No chart data available for APGE.

Trading Snapshot

Day Range: $134.23 – $136.86
52-Week Range: $34.34 – $134.88
Volume: $3.30B
Avg Volume: $2.87B
Shares Outstanding: 75.4M
Next Earnings: Sep 23, 2026

Fundamentals Snapshot

Annual Revenue: $638M
Last Q Revenue: $164M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-4.33
Dividend Yield: —

Why Investors Own APGE

✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$638M▲ +40.4% YoY

Gross Margin (TTM)

66.8%▲ +1.4% YoY

Operating Income (TTM)

$151M▲ +40.4% YoY

Free Cash Flow (TTM)

$153M▲ +40.4% YoY

About APOGEE THERAPEUTICS INC

Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.

🦦